By Raffaele Pace,VP of Operations Engineer, Stevanato Group
Combination products are on the increase for a range of therapies – from low-volume orphan drugs to high-volume pharmaceuticals and the latest biologics and biosimilars.
In particular, the demand for injectables has been growing over the last few years – largely due to an increase in chronic diseases that often require regular self-administration to ensure proper treatment. The most widespread is diabetes, which has long been a problem in the developed world and is now becoming more common in developing, large-population nations like India and China. Other instances where self-administration of injectables comes into play include the growing niche of targeted small-batch and even personalized medicines, including oncological formulations and certain biologics*.